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What causes a low TSH level 
with a normal free T4 level?
❚ Evidence summary
The decreased TSH level seen in SCH
results from the pituitary’s response to
minor elevations in serum or tissue T4 and
T3 levels.1 Although these levels remain
within the normal range, the increases are
sufficient to decrease the serum TSH level.
The prevalence of SCH depends on the
level of TSH used as a threshold. When the
lower limit of TSH is set at 0.4 mIU/L, the
prevalence was 3.2%.2 When followed up
at 1 year, 40% to 60% of subjects with
suppressed TSH levels will have normal
TSH values.3 Progression to overt hyper-
thyroidism is uncommon, occurring in
4.3% of subjects at 4 years.4 It is worth
noting that individuals treated with
levothyroxine have a prevalence of iatro-
genic SCH from 14% to 21%.5
In patients with SCH aged >60 years,
Subclinical hyperthyroidism (SCH) is
defined as a low thyroid-stimulating 
hormone (TSH) level with normal 
free T4 and free T3 levels in patients 
without specific symptoms of 
hyperthyroidism. There is no evidence 
that treating SCH results in improved 
cardiovascular outcomes and evidence is
insufficient that it improves neuropsychiatric
outcomes (strength of recommendation
[SOR]: C).
Bone mineral density may be increased
with treatment of SCH (SOR: B, based on
one randomized clinical trial).
Early detection and management 
of SCH is important
SCH is one of those subclinical diseases
commonly encountered in primary care; 
it is more common in women than men, in
blacks than whites, and in the elderly. It is
less common, however, than subclinical
hypothyroidism. Early detection and 
management of SCH is important for 
several reasons. First of all, with careful
history taking and a thorough laboratory
follow-up, other hidden thyroid diseases
and medication problems may be found
and prevented. Second, the cardiovascular
abnormalities related to this disease may
precede the onset of a more severe car-
diovascular disease. Third, it is becoming
apparent that this disease may accelerate
the development of osteoporosis, particu-
larly in postmenopausal women. Finally, as
I have learned from my clinical experience,
if patient and family are not counseled 
properly, they may become confused 
and abandon follow-up or treatment.
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treating subclinical
hyperthyroidism
improves 
cardiovascular
outcomes
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the cumulative incidence of atrial fibrillation
after 10 years varied with the serum TSH
level: it was 28% in those with serum TSH
<0.1 mIU/L; 16% in those with values
between 0.1 and 0.4 mIU/L, and 11 % in
those with normal values.6 Patients with
SCH have been reported to have increased
heart rate, contractility, left ventricular mass,
and increased risk of diastolic dysfunction
and atrial arrhythmias.7 Patients aged >60
years with at least 1 suppressed TSH value
have an increase in mortality over 5 years
(standardized mortality ratio [SMR]=1.8;
95% confidence interval [CI], 1.2–2.7). At
10 years, the SMR was 1.2 (95% CI,
0.9–1.7). It appears that this is primarily
related to cardiovascular mortality.8
There are little data on the effects of
treating SCH. One study of post-
menopausal women with endogenous
SCH (defined as TSH <0.1 mIU/L) ran-
domly assigned women to take methima-
zole (Tapazole) or placebo. Both groups
were followed for 2 years and none
received any medication with known
effects on bone metabolism in the past or
during the study period. The untreated
patients with SCH had significantly higher
bone mineral density loss (>5%) at both
18 and 24 months.9
Recommendations from others
A systematic review suggests the following
regarding the evaluation and treatment of
SCH.10
1. Exclude other causes of subnormal
serum TSH concentration (TABLE) 
2. Retest patients. Patients with atrial
fibrillation, and cardiac disease, or a TSH
<0.l mIU/L should be retested in 2 to 4
weeks. Other patents can be retested in 3
months.
3. Patients whose TSH remains <0.1
mIU/L should undergo a radioactive iodine
uptake scan. If the uptake is high (consis-
tent with Graves’s disease or a focal nod-
ule), treat as appropriate for that disease. 
Younger patients (<60 years), with
mild TSH suppression (0.1–0.45 mIU/L)
or low radioactive iodine uptake can be
followed with serial TSH testing at 3- to
12-month intervals. However, for these
patients who also have cardiac disease,
decreased bone mineral density, or symp-
toms suggestive of hyperthyroidism, thy-
roid suppression is recommended.
In patients aged >60 years with TSH
<0.1 mIU/L, antithyroid treatment should
be considered to decrease cardiac and bone
loss complications. 
Patients receiving thyroid replacement
therapy should have their dose adjusted to
maintain a normal serum TSH concentra-
tion. However, when thyroid hormone
therapy is used for TSH suppression to
prevent or reduce goiter growth or prevent
recurrence of thyroid cancer, then a lower
TSH may be unavoidable. The adverse
effects can be minimized by treatment with
the least level of suppression necessary to
meet the desired goal. ■
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